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Abstract
Background: Greenhouse gas (GHG) mitigation policies can provide ancillary benefits in terms of
short-term improvements in air quality and associated health benefits. Several studies have analyzed
the ancillary impacts of GHG policies for a variety of locations, pollutants, and policies. In this paper
we review the existing evidence on ancillary health benefits relating to air pollution from various
GHG strategies and provide a framework for such analysis.
Methods: We evaluate techniques used in different stages of such research for estimation of: (1)
changes in air pollutant concentrations; (2) avoided adverse health endpoints; and (3) economic
valuation of health consequences. The limitations and merits of various methods are examined.
Finally, we conclude with recommendations for ancillary benefits analysis and related research gaps
in the relevant disciplines.
Results: We found that to date most assessments have focused their analysis more heavily on one
aspect of the framework (e.g., economic analysis). While a wide range of methods was applied to
various policies and regions, results from multiple studies provide strong evidence that the short-
term public health and economic benefits of ancillary benefits related to GHG mitigation strategies
are substantial. Further, results of these analyses are likely to be underestimates because there are
a number of important unquantified health and economic endpoints.
Conclusion: Remaining challenges include integrating the understanding of the relative toxicity of
particulate matter by components or sources, developing better estimates of public health and
environmental impacts on selected sub-populations, and devising new methods for evaluating
heretofore unquantified and non-monetized benefits.
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Background
Averting the course of climate change would result in
human health benefits directly associated with lessened
global temperature changes and associated impacts, but
would also bring ancillary health benefits from reduced
ground-level air pollution in the short-term [1-5]. Many
fossil-fuel combustion processes that generate greenhouse
gases (GHG) also emit other harmful air pollutants. Sev-
eral measures aimed at reducing GHG emissions can also
improve local air quality, most commonly particulate
matter (PM) and ozone (O3) precursors. Further, whereas
the benefits from climate change mitigation would mate-
rialize far in the future, co-benefits, or ancillary benefits,
would occur in the short-term.
Figure 1 describes the relationships among the health con-
sequences of climate change and air quality policies and
the general framework of how these responses can be
assessed. Air quality policies are routinely evaluated in
terms of the estimated health outcomes avoided and their
economic impact [6,7]. However, assessment of the
health impacts of GHG strategies often considers only
consequences in the far future (i.e., left side of Figure 1),
without integration of the short-term benefits of related
policies [8]. Well-informed public health and environ-
mental strategies require full consideration of conse-
quences, including co-benefits and potential ancillary
harms.
A broad array of tools to evaluate the health-related ancil-
lary costs and benefits of climate change is currently avail-
able, and some examples are provided in italics in Figure
1. The general structure for most assessments involves
three key steps: (1) estimating changes in air pollutant
concentrations, comparing levels in response to GHG mit-
igation to concentrations under a baseline "business-as-
usual" scenario; (2) estimating the adverse health impacts
avoided from reduced air pollution; and (3) for some
studies, estimating the monetary benefit from these
averted health consequences, often with comparison to
the cost of the climate change mitigation measure. The
first step is sometimes accomplished through emissions
scenarios and information regarding how emissions
translate into pollutant concentrations, such as with air
quality modeling systems. The second step usually relies
on concentration-response functions from existing epide-
miological studies on ambient air pollution and health.
The third stage utilizes a variety of techniques to translate
health benefits into monetary terms, such as contingent
valuation (CV). Additional steps include sensitivity analy-
sis, such as applying multiple climate change scenarios or
concentration-response functions for health effects.
This paper aims to illuminate the weight of evidence on
the ancillary health benefits of GHG policies, provide a
framework for such analysis, and critique relevant meth-
ods. We focus on the effects of air quality; however a full
assessment of the complete ancillary consequences would
consider other factors such as the cost of mitigation meas-
ures and ecological impacts. We close with recommenda-
tions on the appropriate role of ancillary health benefits
and costs in the climate change mitigation debate. As part
of these recommendations, we identify a number of pub-
lic health and economic related research topics that
require clarification in order to promote more effective
ancillary benefits assessments with respect to GHG miti-
gation policies.
Studies of ancillary benefits
A variety of studies have been conducted to estimate the
health and air pollution ancillary benefits from GHG
reduction, with a wide range of methods and study areas.
Energy scenarios, emission inventories, and global change
and regional air quality modeling systems have been
linked to estimate the short-term incremental changes in
public health and the environment that could result from
various GHG mitigation policies [9,10].
Recently, the Stern Review [11] addressed a wide range of
global benefits and costs associated with climate change,
including air pollution co-benefits. Citing a study by the
European Environmental Agency, the Review notes that
limiting global mean temperature increase to 2°C would
lead to annual savings in the implementation of existing
European air pollution control measures of €10 billion
and additional avoided annual health costs of €16–46
billion. Even larger co-benefits are estimated in develop-
ing countries, including via the substitution of modern
fuels for biomass. The Stern Review also recognizes some
of the trade-offs between climate change objectives and
local air quality gains. For instance, switching from petrol
to diesel reduces carbon dioxide (CO2) emissions but
increases particles with aerodynamic diameter ≤ 10 μm
(PM10) and nitrogen oxides (NOx) emissions. Increasing
combustion temperatures of aircraft engines reduces CO2
while increasing NOx, as well as water vapor, which can
intensify warming effects. Other GHG mitigating actions
present fewer environmental trade-offs (e.g., reductions in
aircraft weight can decrease CO2 emissions and simultane-
ously improve local air quality).
A study of three Latin American cities identified signifi-
cant health benefits from reducing GHG, including about
64,000 cases of avoided premature mortality over a 20-
year period [12]. Reducing methane concentrations by
20% starting in 2010 was estimated to lower tropospheric
O3 levels, averting over 30,000 deaths worldwide in 2030
alone [13]. Country-wide assessments of GHG mitigation
policies on public health have been produced for Canada
[14] and selected energy sectors in China [15,16], underEnvironmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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differing baseline assumptions. A synthesis of research on
co-benefits and climate change policies in China con-
cluded that China's Clean Development Mechanism
potentially could save 3,000–40,000 lives annually
through co-benefits of improved air pollution [17]. Sev-
eral studies investigated the links between regional air
pollution and climate policy in Europe [18-20]. The table
in additional file 1 summarizes key examples of co-bene-
fits studies and briefly describes the methods used for
each step of analysis.
Results from co-benefits studies are typically difficult to
compare, even if study area and target year are identical,
due to variations in study design. Major differences exist
in the methodology used to estimate benefits, as demon-
strated in the table in additional file 1. Whereas some
studies implement sophisticated modeling systems to
estimate altered air quality, capturing regional differences
in pollutant levels [13], others use simple target values
with uniform pollution reductions across all spatial areas
[12]. Likewise, some studies estimate changes in health
impacts based on a single or small number of concentra-
tion-response functions, capturing only a portion of the
health impacts and at times assuming that concentration-
response functions derived from one area are applicable
in others [21], while other analyses select locally devel-
oped concentration-response functions where available
and consider a wide range of health impacts [12]. Each
approach depends on different underlying conjectures.
Even with the widely varying methods, results consistently
indicate significant ancillary health benefits from GHG
policies. Similarly, estimates of the social cost of air pollu-
tion policies were found to be quite insensitive to choices
in the uncertainties of costs and benefits [22].
Estimation of changes in air pollutant concentrations
Reductions in local air pollutants resulting from GHG
policies (step 1 in Figure 1) can be calculated based on the
resulting pollutant levels under a baseline and climate
mitigation scenarios. Research designs differ not only by
the policy studied but the choice of a baseline "business-
as-usual" scenario. Options range from assumptions that
emissions or pollutant concentrations remain at current
levels, perhaps adjusted for population growth, to aggres-
sive air pollution control policies regardless of actions
taken to affect GHGs. A review of studies of ancillary ben-
efits concentrating on the energy sector found that choice
of baseline scenario greatly impacted results, especially for
studies assuming lower pollution levels as directed by the
1990 Clean Air Act Amendments (CAAA) in comparison
to those omitting the CAAA [23].
Uncertainties in climate change predictions and estima-
tion of regional parameters can be considerable, espe-
cially for highly disaggregated assessments with long-term
projections [24-26]. However, assessment of ancillary
benefits requires estimates of pollution levels a few years
into the future, not several decades, and thus is not
marred by uncertainties that plague many other forms of
climate-related research. The longest projections for stud-
ies in Additional file 1 are about 20 years.
Approaches to estimate changes in air pollution range
from complex modeling systems to a simple pollution tar-
get, assuming a pollutant's levels will be at a specified con-
centration or meet a certain absolute or relative reduction
by a given date. Existing emissions inventories and source-
receptor matrices can be used to connect changes in emis-
sions to changes in specific pollutants [27-31]. Backwards
trajectory modeling has been used to determine pollutant
sources and locations [32-36], and this information can
then be used to estimate how changes in pollutant emis-
sions will affect concentrations at various locales.
Regional air quality modeling systems, such as the
USEPA's Models-3/Community Multi-Scale Air Quality
(CMAQ) model in conjunction with meteorological mod-
els, link data on meteorology, emissions, and land-use to
generate gridded estimates of pollutants, including O3
and PM at various size fractions [37]. Such modeling has
been used to estimate how changes in emissions scenarios
Relationship between climate change and air quality policies Figure 1
Relationship between climate change and air quality policies.
Climate change policies
Aim: reduce GHG emissions.
Regional, national, and
international efforts.
(e.g., Carbon tax)
Air quality policies
Aim: reduce pollutant levels.
Regional and national efforts.
(e.g., changes in public 
transportation use and 
vehicle fleet)
Greenhouse gas 
levels
Air pollutant levels
(e.g., PM, O3,
SO2, NO2, etc.)
Human health response
(e.g., premature mortality, 
frequency of asthma attacks)
Future Short-term
Economic assessment
Valuation of avoided 
adverse health outcomes, 
cost of policy implementation
E.g., air quality 
modeling,
source-receptor matrix
E.g., concentration-response 
functions from epidemiology
E.g., willingness-to-pay, 
cost-of-illness
E.g., explicit 
target,
modeling systems
E.g., Estimate of 
cost of purchase, 
installation, and 
maintenance of 
air pollution 
control
technology
E.g., Evaluation 
of mitigation 
costs by sector
1
2
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affect ambient concentrations [38,39] and similarly can
be applied to estimate future changes in ambient pollut-
ants from climate change measures [40] and future
impacts on human health [41].
The choice of method to ascertain future pollutant levels
depends on what pollutants and regions are considered
and the spatial and temporal resolution desired. For
example, a recent study [13] applied a sophisticated air
quality modeling system to estimate O3 levels across dif-
ferent regions of the world, whereas other approaches
[12,42] applied uniform reductions assuming equal per-
cent reductions in pollutants across all areas. The more
advanced approach using modeling systems is better
equipped to capture spatial variability and transport of
pollution and precursors; however some pollutants are
more easily modeled than others.
Uncertainties in the translation of a given climate policy
to changes in pollutant concentrations vary by the
method used, but include: (1) the choice of "baseline"
scenario; (2) translation of a policy into emissions
changes in various sectors; (3) physical transformation of
the pollutant (e.g., agglomeration of particles to a larger
size); (4) chemical transformation of pollutants (e.g.,
non-linear transformation of O3 precursors, conversion of
gaseous pollutants such as NOx to particles); and (5) spa-
tial and temporal distribution of impacts, as a function of
the preceding factors. Both the baseline scenario and cli-
mate change mitigation policies are assumed to have uni-
form or otherwise known spatial and temporal
distribution in pollution levels. This can be particularly
important if emissions trading is included, such as SO2
cap and trade programs, which set a maximum value for
emissions but allow large heterogeneity in emissions that
can change with time. The level of uncertainty may differ
by pollutant depending on their spatial heterogeneity. For
example, within-city gradients have been observed for
PM2.5 [43]. While most ancillary studies to date have
examined policies at the federal level, in theory analysis
could examine the impacts of other mitigation actions
such as those conducted at the local level [44,45] or even
personal choice and household level actions [46,47] that
aggregated lead to lower GHG emissions.
Estimation of human health impacts
Studies of the health effects potentially avoidable by cli-
mate change mitigation strategies have been based almost
exclusively on concentration-response functions derived
from published epidemiological studies (step 2 of Figure
1). Common urban air pollutants likely to be impacted by
GHG policy (e.g., PM) have been associated with a wide
range of harmful health impacts including increased fre-
quency of hospital admissions and increased risk of mor-
tality [48]. Table 1 provides the health outcomes and
sources of concentration-response coefficients employed
for the subset of studies in additional file 1 that estimated
health impacts. Because mortality dominates benefits
analyses, additional detail is given on the pollutants and
timeframe of exposure (i.e., acute or chronic) for mortal-
ity.
In this context, the method involves applying a mathe-
matical relationship between pollution levels associated
with various types of health endpoints, with an under-
standing of the relationships between the health effect
and individual (or social) preferences for reducing the risk
or incidence of this effect. The use of a concentration-
response function without adjustment assumes that the
underlying relationship between air pollution and health
when and where the function was derived will hold in the
future, perhaps in a different location. This integration
involves matching as closely as possible the starting point
of the valuation analysis to the endpoint provided by
health science, that is a measure of pollution (e.g., ambi-
ent levels as a surrogate for exposure) to a health response
(e.g., increased risk in hospitalization). In addition, the
approach requires knowledge of the population by
cohorts that map to the health endpoints (e.g., asthmatics
or those >65 years) and assumptions regarding baseline
health responses.
Critical differences in this stage of analysis are choice of
pollutants, health effects, time scale (e.g., acute versus
chronic), epidemiological studies, and assumptions (e.g.,
baseline mortality rate). Almost all studies in Table 1 esti-
mated averted mortality for PM, however a variety of
exposure-response coefficients were used, and several
studies made assumptions regarding conversion of one
pollution form to another (e.g., equal toxicity for nitrates
and PM10 [23], PM2.5/PM10 = 0.6 [49], PM10/TSP = 0.5
[15]).
Criteria for selection of health endpoints and epidemio-
logical studies were not consistent across the studies, how-
ever common themes were: (1) use of locally conducted
studies where possible; (2) health endpoints with a con-
sistent literature demonstrating a relationship with air
pollution; and (3) emphasis on peer-reviewed research,
although some studies applied non-peer-reviewed work.
As the epidemiological literature grows, integrated assess-
ments that incorporate these findings also evolve. For
example, earlier studies estimating averted mortality from
lowered O3 levels were based on epidemiological research
of a single city (e.g., a Los Angeles study [50] applied to
Latin America [12,42]), whereas more recent work uses
multi-city epidemiological studies to generate global esti-
mates (e.g., a 95-city study [51] applied worldwide [13]).
Concentration-response functions derived from numer-
ous cities have advantages over single-city studies as theyEnvironmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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are less subject to sample size concerns and city-specific
results can be combined to generate an overall estimate
accounting for within-city and between-city statistical
uncertainty [52]. The choice of location of the epidemio-
logical studies used may be based on selecting a city or
region matching or similar to that of the ancillary benefits
assessment. If only non-local single-city studies are avail-
able, options are to perform a meta-analysis to generate
an average that accounts for the uncertainty of each city-
specific relative rate or to select an existing multi-city
study.
An alternative to identifying epidemiological studies
through literature review is to apply an existing database
or model of concentration-response functions, many of
which also include economic valuation tools. The Fast
Environmental Regulatory Evaluation Tool (FERET) is a
cost-benefit template developed by Carnegie Mellon Uni-
versity and the University of Washington to evaluate how
policy changes affect air-related health outcomes and their
associated economic impacts [53]. The Benefits Mapping
and Analysis Program (BenMAP), developed by USEPA,
estimates population-level exposures, changes in health
endpoints, and economic values [54]. The Ozone Risk
Assessment Model (ORAM) uses air quality modeling to
predict changes in O3  levels and associated health
response [55]. These systems can be used to estimate
changes in health and their monetary value, or as a source
of concentration-response and economic value functions
[55-57].
A number of key uncertainties characterizes the use of
population-based research on air pollution and health for
ancillary benefits studies. These include [58,59]:
Causality
The precise physiological mechanism(s) by which air pol-
lution could cause the health effects indicated in epidemi-
ologic studies is not always fully understood. As a result
causal inferences are generally developed based on con-
sistent evidence across multiple epidemiological studies
including different areas and study designs, and results
from toxicological and human exposure studies in con-
junction with the criteria of biological plausibility.
Other pollutants and pollutant mixtures
Often co-pollutants are included in integrated assess-
ments separately and their health or economic conse-
quences summed. This may underestimate or
overestimate actual damages. The true harmful agent may
not be the pollutant under study but a related pollutant or
group of pollutants with similar sources and/or formation
pathways. For example, O3 can be considered a marker for
an array of photochemical pollutants. Nitrates and sul-
fates are related to PM as they contribute to secondary par-
ticles. Interaction between multiple pollutants is not well
understood, and most results are presented for an individ-
ual pollutant, although air pollution is experienced as a
mixture.
Toxicity relating to PM chemical composition
While a substantial literature provides consistent evidence
that particles are detrimental to health and a limited
number of population-based studies have examined PM
effects by chemical composition [60], the differential tox-
icity of various forms of the PM mixture is unidentified.
Differential effects have been demonstrated based on par-
ticle size, however chemical composition also appears to
play a role as the same size distribution provides different
effect estimates based on region [61,62]. In current analy-
sis of ancillary benefits, all particles of a given size (e.g.,
PM2.5) may be treated with equivalent toxicity, however if
for example sulfates are more harmful than other parti-
cles, technologies that reduce emissions of particles from
coal combustion may result in greater health benefits than
other technologies. If, for example, elemental carbon is
identified to be more detrimental to health, transporta-
tion technologies may be more effective.
Use of ambient monitors
The vast majority of epidemiological studies applied in
ancillary benefits studies use ambient monitoring data as
a surrogate for individual or community-level exposure.
The relationship between personal exposure and ambient
monitoring data varies by pollutant, typically with better
correlation for particles than for O3 [63,64]. Use of ambi-
ent monitors increases the possibility of exposure misclas-
sification, which if non-differential would generally drive
effect estimates towards the null, resulting in underesti-
mates. This issue has particular importance for the extrap-
olation of concentration-response functions from one
area to another, as the relationship between ambient
monitors and exposure, and thereby health, is a function
of indoor pollution and indoor/outdoor activity patterns,
which may vary widely across populations.
Shape of concentration-response functions
Many concentration-response functions applied in ancil-
lary benefits studies assume a log-linear relationship
between exposure and risk. If the true shape differs, incor-
rect estimates could be obtained. If the assessment
includes pollutant levels above those used to generate the
concentration-response function, results will be distorted
if the log-linear or otherwise assumed function does not
hold. If there exists a safe level below which pollution
does not adversely impact health, calculations based on
functions assuming no threshold would be incorrect for
pollutant levels below the threshold value. Some studies
have examined the shape of the concentration-response
curve, however such analysis does not exist for all pollut-Environmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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ants and health outcomes. Several recent US-based studies
found no evidence of a threshold at typical concentrations
for the relationship between mortality and O3 [65] or PM
[66].
Temporal or spatial extrapolation
Pollution and health relationships developed in one area
may not be applicable in another location due to differ-
ences in the underlying population and pollutant charac-
teristics [67]. Efforts are often made to apply locally-
derived studies [49], however concentration-response
functions do not exist for many outcomes and pollutants
for much of the world. Therefore US and European studies
are generally employed, although a growing number of
epidemiological studies are underway in Asia and Latin
America [68-71]. Uncertainties introduced by such extrap-
Table 1: Concentration-response functions used in the assessments listed in Additional file 1
Mortality Morbidity
Aaheim et al. 1999 [153]
PM: Adult and infant [160] Lung-cancer, acute and chronic respiratory symptoms, pseudo-croup, 
asthma [160]
Aunan et al. 2004 [75]
PM10 (chronic): modified version of Pope et al. 1995 [160] Outpatient visits, emergency room visits, hospital admissions, work loss 
days, acute respiratory symptoms in children and adults, chronic 
respiratory symptoms in children and adults, asthma attacks [161]
Burtraw et al. 2003 [23]
PM10 and nitrates (acute) [162] NOx: respiratory symptoms, eye irritation days, phlegm days [163]
Cifuentes et al. 2001 [12,42]
PM10 (acute and chronic): Respiratory hospital admissions [171,172], emergency department visits 
[173], chronic adult bronchitis [174], acute bronchitis in children [56], 
asthma attacks [175], work loss days [176], restricted activity days 
(RAD) [177-179], respiratory symptom days [180]
Adults [164-169]
Infants [84,170]
O3 (acute) [50]
Dessus and O'Connor 2003 [155]
PM10 (acute): Based on previously conducted literature reviews [181] Respiratory hospital admissions, emergency room visits, RAD, MRAD, 
clinic visits for bronchitis for children <15 years, respiratory symptoms 
for adults and children, chronic bronchitis, chest discomfort, eye 
irritation, headaches. Based on previously conducted literature reviews 
[181,182]
Dudek et al. 2003 [156]
Did not apply concentration-response functions. Estimated changes in 
mortality based on baseline burden.
Respiratory disease and neoplasm. Did not apply concentration-
response functions. Estimated changes in morbidity based on baseline 
burden.
Mazzi and Dowlatabadi 2007 [157]
PM2.5 (chronic) [167,183,184] Respiratory and cardiovascular (CVD) hospitalizations [185]
McKinley et al. 2005 [49]
PM10 (acute and chronic) [167,183,186] O3 (acute) [187] Chronic bronchitis [188], MRAD [176,178], emergency room visits and 
hospital admissions: previously conducted review [189]
Wang and Smith 1999 [15]
PM (acute and chronic) [190-192] Respiratory hospital admissions [193], emergency room visits [194], 
RAD >16 years [177], acute bronchitis <16 years [195], asthma attacks 
per asthmatic [175,196], respiratory symptoms [180], chronic bronchitis 
>16 years [174]
West et al. 2006 [13]
O3 (acute) [51]
Note: References for health endpoints refer to the concentration-response function applied.Environmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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olation include differences in indoor/outdoor activity pat-
terns, population characteristics, household characteris-
tics that relate to exposure, and the pollution mixture.
Likewise, the study of ancillary benefits involves future
societies that may have dissimilar housing, populations,
health care systems, and pollutant mixtures compared to
the present day or the timeframe of the epidemiological
research.
Chronic and acute effects and exposures
Air pollution exposure can be categorized as short-term
(i.e., a few days) or longer term (i.e., a few months or
years). Health impacts can be classified as those that take
place immediately or a short time after exposure, or those
that have a gradual or much-delayed response, such as
cancer and neurological disease. Cohort studies of PM,
which evaluate long-term exposure, generally provide
higher estimates for mortality than do time-series studies,
which evaluate short-term exposure [72,73]. Often more
information is available regarding health impacts of
short-term exposure because such exposure estimates are
more readily available. However, the use of only acute-
exposure impacts may underestimate the total mortality
burden from air pollution [74]. Co-benefits studies have
used different approaches to address chronic and acute
health impacts. Whereas one study [75] included esti-
mates of chronic mortality, excluding acute mortality
effects, another [23] incorporated acute mortality only.
Unknown health endpoints
While air pollution has been quantitatively linked to
many health consequences, there are other health events,
including several pediatric and neurological endpoints,
for which concentration-response functions have not yet
been developed. Some of these health responses are less
severe than the more commonly studied effects. However
as a counter example, recent studies elucidated the link
between O3  and mortality [51,76-78]. Although less
severe health endpoints have lower monetary valuations
than more severe impacts, they often occur in larger num-
bers. Thus, the more grave outcomes such as death and
hospital admissions are best viewed as indicators of the
much broader spectrum of adverse health effects resulting
from air pollution.
Degree of mortality displacement
The public health burden of mortality associated with air
pollution depends not only on the increased risk of death,
but also on the length of life shortening. Several recent
studies provide evidence that short-term mortality dis-
placement of a few days or less does not account for the
observed PM mortality effect estimates [79-83]. Past eval-
uations of air pollution's effect on life expectancy gener-
ally considered only deaths among adults above 30 years
of age, but some studies [84-86] suggest that infants may
be among the sub-populations particularly affected by
long-term PM exposure, which would indicate a much
larger reduction in life expectancy. Currently, considera-
ble uncertainty remains as to the amount of life-shorten-
ing associated with air pollution.
Economic valuation of avoided adverse health outcomes
To help decision-makers assess policies with a wide array
of consequences, outcomes are often converted into com-
parable formats. Several multi-criteria decision-making
techniques have been applied in the context of climate
change policy [87-90]. Another widely used approach is to
convert health outcomes into economic terms to allow
direct comparison of costs and benefits. Underlying eco-
nomic valuation of health is the concept that individuals
have preferences that extend over environmental quality,
market goods, and other non-market goods. If this
assumption is accepted, in principle it is possible to
deduce how individuals tradeoff health by measuring
how much in the way of other services individuals are
willing to forego to enjoy health benefits. Expression of
these values in monetary terms is used as a surrogate for
what people are willing to give up in alternative real con-
sumption opportunities. The notion that such individual
tradeoffs well describe society's interest in environmental
quality is by no means universally accepted, and contro-
versy surrounds economic valuation and benefit-cost
analysis in particular [91]. For a summary of the economic
argument see [92].
Approaches for economic valuation of health
We identified several approaches for economic valuation
of averted health consequences (step 3 of Figure 1): COI;
human capital; a variety of WTP methods; and quality-
adjusted life year (QALY) approaches.
Cost of illness
The COI method totals medical and other out-of-pocket
expenditures and has been used for acute and chronic
health endpoints. For instance, separate models of cancer
progression and respiratory disease were used to estimate
medical costs from these diseases over one's lifetime [93].
COI incorporates direct medical costs, such as for physi-
cians' visits and medications, and indirect costs, including
lost income from work loss days. However the approach
does not capture other consequences of illness such as
psychological suffering, physical pain, transportation to
medical appointments, dietary restrictions, and expendi-
tures for friends or family acting as caretakers. The
approach can have a welfare theoretic basis, but does not
reflect the full damage of illness, hence results usually
underestimate costs and should be considered a lower
bound. Some COI studies assign a medical expenditure
based on primary diagnosis [94].Environmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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Human capital approach
Early attempts to value mortality risk reductions applied
the human capital approach, which estimates the "value
of life" as lost productivity. This method is generally rec-
ognized as problematic and not based on modern welfare
economics, where preferences for reducing death risks are
not captured. Another limitation is incorporation of
racial- or gender-based discrimination in wages. This
method assigns value based solely on income, without
regard to social value, so unpaid positions such as home-
maker and lower paid positions such as social worker
receive lower values. Because data are often available for
superior alternatives, this approach is rarely used in health
benefit studies.
Willingness to pay
WTP generates estimates of preferences for improved
health that meet the theoretical requirements of neoclas-
sical welfare economics, by aiming to measure the mone-
tary amount persons would willingly sacrifice to avoid
negative health outcomes. Complications arise in analysis
and interpretation because changes in environmental
quality or health often will themselves change the real
income (utility) distribution of society. A valuation proce-
dure that sums individual WTP does not capture individ-
ual preferences about changes in income distribution.
Another complication is that the value of avoided health
risk may differ by type of health event and age. For
instance, in one study WTP to reduce cancer was about a
third larger than that for a similar chronic, degenerative
disease [95]. VSL estimates can be adjusted based on exist-
ing health condition or age, or by the use of a value per
life-year saved [96]. Use of the value of a statistical life year
(VSLY) is very controversial, however, because it implies
that age and WTP are proportionally and inversely related,
although the literature does not support this assumption.
Estimates for children are very limited; however VSLs are
generally higher for children [97] and the empirical liter-
ature suggests that children's values are approximately
twice the value for an adult. WTP measures are theoreti-
cally superior to the "supply-side" measures of health
damage because they can capture the complete value of
health, including pain and suffering.
The hedonic labor market WTP approach relates wage dif-
ferentials to health risk differences across occupations and
industrial/commercial sectors, under the theory that in
competitive labor markets, workers in risky jobs should
receive wage premiums equal to the value they place on
avoiding health risks [98,99]. Such studies can ask work-
ers their perception of health risks to address differences
between perceived and actual risk. These studies are
numerous and form the foundation for most VSL esti-
mates. However, they are problematic for application to
health effects of pollution, because of less directly relevant
behavioral contexts and/or the populations. In particular,
reducing air pollution may lower some health risks dis-
proportionately for older persons who are not in the labor
market. These benefits, furthermore, may be more likely
for people with chronic heart or lung disease and may
have a delayed effect, all of which would not be captured
in the labor market studies.
A small literature of consumer preference studies esti-
mates WTP to reduce health risks from purchases or other
actual consumer decisions (e.g., purchase of smoke detec-
tors [100], driving behavior under different speed limits
[101]). These studies typically find lower VSLs than other
approaches [101]. A difficulty about these studies is statis-
tically separating the health risk-reducing attribute from
other valued attributes. A large body of literature applies a
hedonic property value approach [102], which provides a
revealed WTP for air pollution reductions but is depend-
ent on housing market perceptions about pollution and
links to non-health effects.
The stated preference WTP approaches, of which CV and
choice experiments are most prominent, are survey meth-
ods presenting hypothetical choices (e.g., willingness to
pay some amount or prefer one set of attributes over
another) to recover preferences for health risk reductions.
Results can be sensitive to question wording and ordering,
and cognition difficulties when understanding small
changes in probabilities are required. However these
methods can be molded to a particular population or con-
text. Respondents can be tested for their cognition and
understanding of the survey's concepts.
Some of the best known stated preference studies for mor-
tality examine traffic fatalities [103,104] and fewer studies
are available for air pollution contexts [105-108]. A CV
survey found that WTP was higher when death risk reduc-
tion takes place now rather than later in life or if the indi-
vidual was mentally healthy [109]. Age had a relatively
minor effect on VSL, and physical health status had no
effect. These results are consistent with those from a study
of adults in the US and Canada, which did not find strong
evidence that WTP is lower for older persons or for those
with chronic heart or lung conditions or cancer [110]. A
recent WTP study of three countries also found that VSL is
not significantly lower for older populations, however
persons admitted to the hospital or emergency room for
CVD or respiratory causes had higher VSL [111]. The first
study to investigate WTP for increased life expectancy
(one year in expectation) added between ages 75 to 85
years found implied VSLs to range from $70,000 to
$110,000, but did not provide indication of whether
respondents understood the complex scenario, and
offered respondents an unrealistically large reduction in
risk [106].Environmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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Two studies applied choice experiments to examine WTP
to reduce risks of chronic respiratory disease [112,113].
Subjects chose between two cities for residence, both pre-
ferred to their present city and differing in risk of develop-
ing chronic bronchitis or respiratory disease and in one
other characteristic: the probability of dying in an auto-
mobile accident or cost of living. Several studies evaluated
the WTP to reduce cancer morbidity risks [114,115].
Three of the first CV studies for acute health responses
used bidding procedures to elicit values for respiratory-
symptom days, with average estimates from $5 to $25
depending on the symptom, its severity, and whether a
complex of symptoms is experienced [116-118]. CV tech-
niques have advanced since these studies, however they
offer consistent ranges of WTP estimates. In one of the few
European studies of this type, over 1,000 Norwegians
were interviewed to ascertain WTP to avoid various ac ute
health effects (e.g., one more day over their usual annual
frequency). The values for avoiding symptoms are slightly
smaller than those found in older US studies, but the asth-
matic values are far larger [119]. A survey of 832 Taiwan-
ese investigated WTP to avoid participants' most-recent
episode of acute respiratory illness [120]. Statistical tech-
niques are used to relate these values to the duration and
severity of the episode and other variables.
Another approach is the averting-behavior method, which
infers WTP by observing and placing values on behavior
used to avoid adverse health outcomes. For instance, if
someone stays indoors with the air conditioner on
because of high air pollution, the added electricity costs
might relate to WTP to avoid health impacts. Defensible
estimates under this approach require stringent assump-
tions, and in practice the method is rarely used, particu-
larly in an acute-health context.
Quality-adjusted life year
The QALY approach attempts to account for the quality of
life lost by adjusting for time "lost" from disease or death.
This method is welfare-theoretic only under very restric-
tive assumptions, so it is difficult to conceptualize the sig-
nificance of any particular QALY score. The estimates may
be very insensitive for distinguishing among different
severities and types of acute morbidity. See the recent
Institute of Medicine report [121] for a full review of this
approach as it could be applied in a regulatory, cost-ben-
efit analysis setting.
A QALY analysis of USEPA's Heavy Duty Engine/Diesel
Fuel regulations found that for situations in which mor-
tality dominates other health outcomes, QALY and WTP
methods can provide similar results [122]. If morbidity
and non-health consequences are predominant, results
from QALY and WTP analysis may differ. Another use of
QALYs investigated over 230 WTP estimates, finding that
variation in WTP values is affected by QALY estimates of
illness severity, illness duration, income, and age [123].
There also exists literature providing QALY estimates for
chronic diseases, for example for various severities of
asthma [124].
Applications of economic valuation
Valuations of mortality risk reductions associated with
environmental policies are usually the largest category of
benefits, both among health responses and compared to
other attributes. For instance, a USEPA analysis of the
Clean Air Act estimated a value of $100 billion annually
for reduced premature mortality out of $120 billion in
total benefits, compared to costs of approximately $20
billion [7]. European and Canadian studies similarly
found that mortality risk dominates analysis of pollution
reductions [125,126]. Next to mortality, reductions in the
probability of developing a chronic respiratory disease
have been estimated to be the most valued, recognizing
that values for other types of diseases are sparse. Reduc-
tions in acute effects are lower valued.
Table 2 provides a sample of values typically used by prac-
titioners of health benefits analyses from several major
studies or models: the USEPA's BenMAP, which is used in
Regulatory Impact Analyses of Regulations [7,54]; the
ExternE model [125], which is used by the European
Union (EU) in its regulatory analyses, taken from its
Clean Air For Europe (CAFÉ) Program (AEA) [127]; the
Air Quality Valuation Model (AQVM) for Canada [126];
the Australian Bureau of Transport and Regional Econom-
ics (BTRE) assessment of transportation-related pollutants
in Australia [128]; and a study of the benefits of environ-
mental improvement in New Zealand [129]. Within the
table, health values are converted to common, compara-
ble currency using purchasing power parity (PPP) and
constant 2000 dollars. The WTP for reducing risks of mor-
tality and chronic morbidity is expressed, for convenience,
as VSL and the value of a statistical case (VSC) of chronic
disease. This term is merely shorthand for the WTP for a
given risk reduction divided by that risk reduction. This
relationship is useful because VSLs or VSCs can be multi-
plied by estimates of the "lives saved" or "chronic cases
saved" to obtain benefits.
The table shows a fairly wide range of VSL values, with the
highest in the US. Rank ordering of values across the other
health endpoints is very similar across studies, although
some different sets of health endpoints are considered
and there are many blank cells (i.e., categories for which
information is unknown or not incorporated) outside of
the US and EU. The relatively close agreement between the
US and EU likely results from reliance on a common pool
of studies, results, and interpretations as well as the socialEnvironmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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cost of electricity studies in the US and the ExternE effort
in Europe, which benefited from close collaboration
between the participating researchers in both efforts
[130,131]. In addition, the Canadian studies were
informed by the AQVM developed by researchers active in
the US social costing debate [132].
Credibility of economic valuation estimates
We evaluated economic valuation methods on three crite-
ria: (i) the degree to which methods are based on prefer-
ences for such health improvements, which we took to be
in agreement with welfare economics principles; (ii) the
number of studies following the technique, which is an
imperfect measure of degree of consensus and attractive-
ness of the technique to researchers; and (iii) additional
major limitations, serving to capture other issues, such as
data shortcomings. Based on this admittedly subjective
judgment, we then rated the reliability of the different
approaches from A (very reliable) to D (unreliable). The
assessment is intended to provide comparison among
approaches, rather than an absolute assessment of accu-
racy.
As a first step of the evaluation, we compared theoretical
predictions and empirical results of economic valuation
studies for mortality (Table 3). Under the theoretical
framework, WTP should increase with the size of the risk
change. The life cycle model also implies lower WTP when
risk change is further in time. Persons facing higher base-
line risks should have higher WTP for a given risk reduc-
tion (the "dead anyway" effect) [133]. Higher incomes or
wealth should relate to higher WTP. With borrowing
against future earnings, the relationship between WTP
and age should be an inverted U-shape according to life
cycle models. Finally, these models do not make a predic-
tion regarding health status.
These theoretical predictions are not always matched by
empirical results, and Table 3 demonstrates that no sim-
ple consistent relationship exists between WTP for mortal-
ity and other factors listed, other than income. This could
be due to differences in the underlying approaches used to
solicit results, or indication of a more complicated system
(e.g., age's impact on VSL may further depend on other
factors). Our subjective evaluation of the valuation meth-
ods for mortality, chronic morbidity, and acute morbidity
are provided in Tables 4, 5, and 6, respectively. No single
method is fully satisfactory. Due to the array of methods
available for estimating the economic impact of health
Table 2: Sample of typically used values for PM-related health impacts (mean estimates) ($2000 PPP-adjusted [197])
Health Effects US EU Canada Australia New Zealand
Mortality: 1,042 1,296,552 (premature 
death) [198]
VSL: Adults 6,300,000 2,247,191 3,480,000 1,439,394 1,717,241 (1,724,138) 
[198]
VSL: Children 2 × adult 4088764 (infant)
VSLY 134,831 70,455 118,621
Morbidity: 1929.55 (average cost/
separation) [199]
Morbidity: children 2 × adults
Chronic bronchitis 340,000 213,483
Chronic asthma 39,000
Respiratory hospital 
admission
14,000 2,247 1,032 2,069
CVD hospital 
admission
21,000 2,247 1,052 2,759
Emergency room visit 300 (asthma) 541 (respiratory) 562 
(CVD)
Doctor's visit 60
RAD 106 92 (working age) 78 
(young, elderly)
22 53
MRAD 50 43
Acute respiratory 
symptom
3–24
Use of respiratory 
medication
1.12
Asthma day 32–74 43 15
References: [54] [127] [200] [128]* [129]
Note: *: VSL derived from population-weighted values in the Australian Bureau of Transport and Regional Economics (BTRE) assessment, Table 3 
[128]. Population data from the Australian Bureau of Statistic.Environmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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and the limitations of any single approach, we recom-
mend the application of multiple methods.
In addition to the issues of credible economic evaluation
of the benefits and costs of climate change policies, a cen-
tral issue in comparing these values is the discount rate
applied [134]. Selection of the discount rate, which
accounts for differential value of costs and benefits occur-
ring in the far future compared to those taking place in the
present or near feature, can greatly alter results of cost ben-
efit analysis, such as for climate change. In fact, a recent
disagreement regarding climate change policy analysis by
two leading economists centered largely on the use of a
different discount rate [11,134]. While some aspects of
benefit/cost analysis are well-suited to monetary terms,
the issue of an appropriate discount rate carries ethical
implications regarding the relative impacts on various
populations.
Discussion
Estimating the ancillary public health consequences of
GHG policies is a challenging task drawing upon expertise
in economics, emission inventories, air pollution mode-
ling, and public health. However, to date most assess-
ments have focused more heavily on one aspect of the
framework (i.e., a portion of Figure 1), whether it be esti-
mation of changes in air pollutant concentrations, health
response, or economic analysis (see Table in additional
file 1). We have summarized the limitations in the health
and economics estimations, however other uncertainties
exist for the selection of policy alternatives and estimation
of changes in air quality. In spite of differences in
approaches, choice of climate change policy, etc., the
wealth of evidence from multiple studies provides a broad
consensus that ancillary health benefits from improved
air quality are substantial, which can be useful informa-
tion for the policy debate about the scope, design, and
timing of climate policy.
Results from current ancillary benefits studies may be
underestimates due to unquantified benefits, as only a
subset of the health consequences from air pollution have
adequate exposure-response relationships [59,135-137].
A USEPA evaluation of the Clean Air Interstate Rule
(CAIR) noted numerous unquantified health impacts
such as chronic respiratory damage for O3, pulmonary
function for PM, and lung irritation for NOx [135]. The
nature of unquantified effects is continually evolving.
Some pollution and health relationships considered
unquantifiable by USEPA in 1999 [7] have since been
identified, such as for acute O3 exposure and mortality
[51,76-78] and air pollution's association with lung can-
cer [138,139]. Further some endpoints may be included
in one analysis, but regarded as too uncertain for another,
perhaps due to a different study location or differences in
researchers' judgment. One approach to address health
endpoints with uncertain concentration-response func-
tions is to include these effects qualitatively in discussion
of unquantified benefits. Another is to incorporate these
effects in sensitivity analysis.
Similarly, some economic costs may not be easily quanti-
fiable, even if the health response to air pollution is
understood. For example, the USEPA's CAIR analysis
identified several unquantifiable costs including employ-
ment shifts as workers become reemployed, administra-
tion costs in state and federal governments, and some
permitting costs [135]. Only a limited number of studies
are available regarding the value of children's health, such
as several that estimated the cost of children's asthma
[140-143]. Valuing reduced mortality risks for newborns
or children is challenging because children are generally
not the key decision-makers over their own health. Tech-
niques to transfer adult monetary valuations to children
have been explored [144].
This work has focused primarily on health benefits from
improved air quality resulting from climate change miti-
Table 3: Theoretical predictions and empirical results of studies estimating value of mortality risk reductions. Source: Hammitt and 
Graham (1999) [103]
Study Size of Risk 
Change
Future Risk 
Change
Baseline Risk Income 
(or proxies)
Age Health Status
Life cycle model: 
Theory
+, proportional - +a +- b, + then -c indeterminate
Empirical Studies
Compensating Wage + N/A -d + - N/A
Other Revealed 
Preference
+ N/A Unknown + + N/A
CV +, not proportional - Varies + + then -, 0, - No effect, +
a. Small "dead anyway" effect: Higher value to benefits while alive than for a bequest [133].
b. With borrowing against future earnings.
c. Inverted U with no borrowing.
d. Self selection by risk tolerant workersEnvironmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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gation, however a full assessment of the short-term conse-
quences of climate change policies would incorporate
tradeoffs that may in fact be negative or for which the
direction of impact is difficult to predict. Policies might
alter unemployment rates and income levels, which have
been linked to increased suicides [145,146], domestic vio-
lence [147,148], depression [149], and mental health
[150,151]. The relationships between low income or
unemployment and health are not fully understood and
somewhat controversial. Still, changes in employment or
income from climate policies have the potential to intro-
duce another set of health-related ancillary benefits or
costs.
As another example, GHG mitigation might incorporate
policies to deter suburban sprawl, which could reduce
transportation-related air emissions and thereby improve
health in the short-term. However, a fuller understanding
of the consequences of such a policy would address
changes in population-weighted air pollution exposure,
which may be higher in urban areas, as well as urban
crime, and other potential impacts from higher popula-
tion density. Other examples are transition to biofuels,
which could have implications for nutrition, or the use of
bikes rather than cars for transportation, which would
lower air pollution emissions but could potentially also
harm health if biking occurred near major roadways,
increasing proximity to high pollution at an increased
ventilation rate, or could improve health through
increased exercise. Thus, while our discussion and most
research of ancillary consequences have focused on bene-
fits, a full suite of positive and adverse consequences
could exist.
One of the most controversial aspects of ancillary benefits
analysis is the valuation of health in non-industrialized
countries. Previous Intergovernmental Panel on Climate
Change (IPCC) assessments sparked heated debate
because they presented non-market values for health
improvements that some thought unethically devalued
lives in non-industrialized countries. Challenges to eco-
nomic valuation of health in these regions are described
elsewhere [152]. Limited data availability, such as for
wages, prohibits application of some approaches. Medical
Table 4: Credibility ratings for approaches to valuing changes in the risk of mortality
Criteria
Approach Welfare Theoretic (Y/N) Numbers of Studies 
(Many/Some/Few)
Other Limitations Rating
Human Capital N M (not recent) Undervalues non-workers D
COI Not usually; in principle could be if 
separate estimates available for pain and 
suffering
M Usually underestimates C
Revealed preference: 
Hedonic Labor Market; 
others
Y M Inappropriate commodity/
Population sampled
B
CV and choice experiments: 
health
Y S Hypothetical; hard to 
understand small probability 
change
B
QALYs N 
(except under very restrictive conditions)
M Monetization arbitrary C
Table 5: Credibility ratings for approaches to valuing changes in the risk of chronic morbidity
Criteria
Approach Welfare Theoretic (Y/N) Numbers of Studies 
(Many/Some/Few)
Other Limitations Rating
COI Not usually; hospitalization; sometimes 
labor productivity 
(which is a revealed preference approach)
M: medical cost studies F: 
labor productivity studies
Pricing medical services can be difficult 
where medical care is socialized or 
subsidized
C-B
Revealed preference Y Many on injury/accidents; 
not on morbidity
C
CV and choice 
experiments: health
Y F See above B
QALYs Y (under very restrictive conditions) M Arbitrary monetization CEnvironmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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cost information may not reflect social opportunity costs.
Hedonic labor market studies, which presume that labor
and goods markets are competitive and workers have rea-
sonable information on death and injury risks, may carry
more uncertainties in some regions than others. Valuation
of the health of various household members, particularly
children, may be quite different than in developed coun-
tries because of children's more central role in the econ-
omy. Rapid economic growth means preferences are
changing as well, raising questions about the applicability
of indigenous studies several years hence.
A related challenge is differential effects by subpopula-
tions. Epidemiological evidence supports the hypothesis
that some segments of the population (e.g., racial or
socio-economic groups) face disproportionate health bur-
dens from air pollution. Current ancillary benefit analysis
does not include separate estimation of health and eco-
nomic damages by sub-groups or confront issues of envi-
ronmental justice. Further information is needed on the
relationship between air pollution and health and eco-
nomic valuation methods with respect to subpopulations.
In order to conduct the most robust ancillary benefits
analyses, we recommend reliance on the most defensible,
transparent methods, even if they are recognized as defi-
cient. Because a variety of approaches are available, none
of which are ideal, we recommend the application of mul-
tiple methods and extensive sensitivity analysis consider-
ing a range of changes in air pollution concentrations,
spatial distribution of impacts (if considered), health end-
points, epidemiological concentration-response func-
tions, and economic valuation estimates.
Conclusion
Overall, though still a work in progress, the present tech-
niques available for the analyses of the ancillary public
health costs and benefits are adequate and appropriate for
implementation by those comparing the relative merits
and overall value of various GHG mitigation policies. Esti-
mates of considerable benefits that remain after a variety
of sensitivity analyses can alleviate some concerns regard-
ing limitations of individual methods or assumptions.
The short-term public health changes associated with
GHG mitigation strategies should be considered as a key
factor in the choice of GHG policies.
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Table 6: Credibility ratings for approaches to valuing changes in the risk of acute morbidity
Criteria
Approach Welfare Theoretic 
(Y/N)
Numbers of Studies 
(Many/Some/Few)
Other Limitations Rating
COI No M Pricing medical services can be 
difficult
C
Revealed preference 
(averting behavior)
Y 
(under restrictive 
conditions)
Many for injury and accidents; not for 
acute respiratory symptoms
C
CV and choice 
experiments: Health
Y S Old methods/studies; some ad hoc 
estimates; small samples
B
QALYs Y 
(under very restrictive 
conditions)
M Scores insensitive to severity of 
acute effects
CEnvironmental Health 2008, 7:41 http://www.ehjournal.net/content/7/1/41
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